About
The Shinozaki Laboratory studies the molecular influence of environmental factors such as trauma, stress, and inflammation on individual susceptibility to psychiatric conditions including major depressive disorder (MDD), post-traumatic stress disorder (PTSD), and delirium using epigenetic/genetic approaches as well as a medical engineering approach through device development and machine learning.
The main focus of the Shinozaki Lab has been to examine epigenetic changes resulting from exposure to stress such as trauma or inflammation to aid in the search of biomarkers of stress exposure and risk for MDD, PTSD, and delirium. Dr. Shinozaki, in collaboration with many colleagues across different fields, successfully developed several ongoing projects in epigenetics/genetics- one in collaboration with neurosurgeons to study DNAm correlation between brain tissue and peripheral tissues, which is supported by NIH R01 funding.
From the angle of neuroinflammation, we are investigating the role of epigenetics in inflammatory processes in delirium and aging. In addition to epigenetics investigation, we are developing a novel electroencephalography (EEG) device to screen delirium among elderly patients in the hospital.
Recent Updates
- July 18, 2025
- CONGRATULATIONS to everyone in the Shinozaki Lab! We are so proud to announce that the following papers have been published in Summer 2025! View the papers below:
- Associations of metformin use history with delirium and mortality in patients with type 2 diabetes mellitus: A retrospective cohort study.
- Seki T, Yamanashi T, Shimura A, Chang G, Santiago TA, Phuong NJ, Nguyen HD, Gorantla N, Nishiguchi T, Yamanishi K, Ishii T, Aoyama B, Inoue T, Shinozaki G.
The age-related susceptibility to postoperative delirium quantified by bispectral electroencephalography correlates with postoperative delirium-like behavior in mice.- Nishiguchi T, Yamanishi K, Shimura A, Seki T, Ishii T, Aoyama B, Gorantla N, Nguyen HD, Phuong NJ, Yamanashi T, Iwata M, Shinozaki G.
July 10, 2025
Congratulations to Nipun Gorantla, who was accepted into the Icahn School of Medicine at Mt. Sinai through their highly competitive FlexMed Early Assurance Program!
July 4, 2025
Dr. Shinozaki delivered a high-impact presentation, “Game changing approach for delirium: prediction of patient outcomes with novel bispectral EEG device and epigenetics mechanism of pathophysiology,” at the Department of Psychiatry, Nagasaki University, Nagasaki, Japan — demonstrating the lab’s leadership on the global stage.